Clinical Trial Update: Double Blind, Randomized, 3 Week Inpatient Study To Evaluate The Safety & Efficacy Of PF-02545920 Compared With Placebo [Phase 2]

View source ↗

Summary

Phase 2 randomized trial evaluating PF-02545920 vs placebo for schizophrenia was terminated; results posted.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Schizophrenia

Drugs mentioned

• PF-02545920

Snippet

Sponsor: Pfizer | Conditions: Schizophrenia | Phase 2 | Status: TERMINATED | Results posted: 2017-12-20